medigraphic.com
ISSN 1561-3119 (Electronic)

2013, Number 2

<< Back Next >>

Rev Cubana Pediatr 2013; 85 (2)

Pulmonary atresia with intact interventricular septum- the clinical relevance of the palliative treatment in our context

González MAE, Selman-Houssein SE, Serrano RG

Language: Spanish
References: 20
Page: 149-162
PDF size: 142.12 Kb.


ABSTRACT

Introduction: pulmonary atresia with intact interventricular septum is a complex congenital cardiopathy at the time of making therapeutic decisions in each case; this is the reason why the successful management of this disease is a problem to be solved by the pediatric cardiology.
Objective: to determine the existing level of clinical relevance of palliative therapies applied in our context.
Methods: evaluation of 43 children with confirmed diagnosis of the disease, who had been referred to "William Soler" pediatric cardiological center and had undergone initial palliative treatment in the period of January 1992 through November, 2011. With the objective of determining the clinical relevance of this procedure, an effectiveness study including the analysis of incidence/prevalence of well-defined events (early mortality and main lethality causes) in each therapeutic variant used in patients was conducted.
Results: performance of surgical fistula associated with atrioseptostomy showed high indexes of clinical relevance.
Conclusions: there were low incidences and prevalence indexes of early mortality and also reduced occurrence of respiratory failures as lethal complication from this combined procedure, compared with the rest of the therapeutic modalities under study.


REFERENCES

  1. Cañedo Andalia R. Medicina basada en la evidencia: un nuevo reto al profesional de la información en salud. Acimed. 2001;9(1):5-11.

  2. Hernández LJ ¿Qué es la Salud Pública Basada en la Evidencia? Rev Salud Pública. 2003;5(1):40-5.

  3. Marzo-Castillejo M, Alonso-Coello P. Clasificación de la calidad de la evidencia y fuerza de las recomendaciones. GRADE Working Group. Aten Primaria. 2006;37(1):1-11.

  4. Sackett DL, Rosenberg WM, Gray JA. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-2.

  5. Portela F, Marcos S. Atresia pulmonar con septo íntegro. Cir Cardiov. 2008;15(4):337-44.

  6. El Louali F, Villacampa C, Aldebert P, Dragulescu A. Pulmonary stenosis and atresia with intact ventricular septum. Arch Pediatr. 2011;18(3):331-7.

  7. Shinebourne EA, Rigby ML, Carvalho JS. Pulmonary atresia with intact ventricular septum: from fetus to adult: congenital heart disease. Heart. 2008;94(10):1350-7.

  8. Petrucci O, O'Brien SM, Jacobs ML, Jacobs JP, Manning PB, Eghtesady P. Risk factors for mortality and morbidity after the neonatal Blalock- Taussig shunt procedure. Ann Thorac Surg. 2011;92(2):642-51.

  9. Burke RP, Hannan RL, Zabinsky JA, Tirotta CF. Hybrid Ventricular Decompression in Pulmonary Atresia With Intact Septum. Ann Thorac Surg. 2009;88:688-9.

  10. Xu WZ, Xia CS, Zhang ZW, Li JH. Efficacy of arterial duct stenting in neonatal pulmonary atresia with intact ventricular septum. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(7):621-4.

  11. Li S, Chen W, Zhang Y, Zhang H. Hybrid Therapy for Pulmonary Atresia With Intact Ventricular Septum. Ann Thorac Surg. 2011;91:1467-71.

  12. Gómez Rinesi JF. Epidemiología Clínica: Riesgo. Revista de Posgrado de la Cátedra de Medicina. 2001;113:5-14.

  13. Tapia Granados JA. Incidencia: concepto, terminología y análisis dimensional. Med Clin. 1994;103:140-2.

  14. Abraira V. Medidas del efecto de un tratamiento (I): reducción absoluta del riesgo, reducción relativa del riesgo y riesgo relativo. SEMERGEN. 2000;26:535-6.

  15. Baptista González HA. El número necesario a tratar (NNT) y número necesario para hacer daño (NNH). Valoración de la magnitud de la relación beneficio vs. riesgo en las intervenciones médicas. Revista de Investigación Médica Sur, México. 2008;15:302-5.

  16. Coutinho LMS, Scazufca M, Menezes PR. Methods for estimating prevalence ratios in cross sectional studies. Rev Saúde Pública. 2008;42:6.

  17. Tapia Granados JA. Medidas de prevalencia y relación incidencia- prevalencia. Med Clin. 1995;105:216-8.

  18. Abraira V. Medidas del efecto de un tratamiento (II): odds ratio y número necesario para tratar. SEMERGEN. 2001;27:418-20.

  19. Barton S. Which clinical studies provide the best evidence? BMJ. 2000;321:255-6.

  20. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd. ed. Baltimore: Williams and Wilkins; 1996. p. 39-49.




2020     |     www.medigraphic.com